Ryan Hays

Ryan Hays

Neurology, The University of Texas Southwestern Medical Center, Dallas, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
DDDivyanshu Dubey
Divyanshu Dubey
AAAbdulradha Alqallaf
Abdulradha Alqallaf
RHRyan Hays
Ryan Hays
MFMatthew Freeman
Matthew Freeman
KCKevin Chen
Kevin Chen
SVSteven Vernino
Steven Vernino
It is estimated that epilepsy of unknown etiology constitutes one-third of all epilepsies in adults.1 This represents a significant disease burden, with treatment limited to symptomatic antiseizure medications. A subgroup of these patients may have immune-mediated neuronal dysfunction.1-3 Quiz Ref ID Recently, a number of neurological autoantibodies (Abs) have been described in association with autoimmune encephalopathy or epilepsy.3 A majority of these antibodies are directed against neuronal cell surface antigens, including synaptic neurotransmitter receptors, ion channels, or related proteins. Another group of these patients have antibodies specific for intraneuronal nuclear or cytoplasmic antigens.4,5 Additionally, patients with steroid-responsive encephalopathy associated with autoimmune thyroiditis or patients with high levels of glutamic acid decarboxylase 65 (GAD65) Abs can present with seizures.6-9 Identification of these immune-mediated syndromes is important because early diagnosis and treatment appears to be associated with better clinical outcomes.

6 May 2010 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
MNMaromi Nei
Maromi Nei
RHRyan Hays
Ryan Hays

1 July 2015 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
DDDivyanshu Dubey
Divyanshu Dubey
NSNiyatee Samudra
Niyatee Samudra
PGPuneet Gupta
Puneet Gupta
MAMark Agostini
Mark Agostini
KDKan Ding
Kan Ding
RHRyan Hays
Ryan Hays

1 January 2020 in Epilepsy & Behavior
Verified
Journal Article
Closed access
CACaroline Abe
Caroline Abe
DDDavid Denney
David Denney
ADAlexander Doyle
Alexander Doyle
MCMunro Cullum
Munro Cullum
JAJessica Adams
Jessica Adams
KDKan Ding
Kan Ding

21 July 2016 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
DDDivyanshu Dubey
Divyanshu Dubey
ZFZehra Farzal
Zehra Farzal
RHRyan Hays
Ryan Hays
LBL Steven Brown
L Steven Brown
SVSteven Vernino
Steven Vernino
The objective of this study was to analyze published literature on autoimmune epilepsy and assess predictors of seizure outcome. From PubMed and EMBASE databases, two reviewers independently identified publications reporting clinical presentations, management and outcomes of patients with autoimmune epilepsy. A meta-analysis of 46 selected studies was performed. Demographic/clinical variables (sex, age, clinical presentation, epilepsy focus, magnetic resonance imaging [MRI] characteristics, time to diagnosis and initiation of immunomodulatory therapy, and type of immunomodulatory therapy) were compared between two outcome groups (responders and nonresponders). Clinical response was defined as >50% reduction in seizure frequency. Unstandardized effect sizes were collected for the studies for responder and nonresponder groups. Sample size was used as the weight in the meta-analysis. The random effects model was used to account for heterogeneity in the studies. The 46 reports included 186 and 96 patients in responder and nonresponder groups respectively. Mean age of the responders and nonresponders was 43 and 31 years (p < 0.01). Responders were more likely to have cell-surface antibodies (68% versus 39%, p < 0.05), particularly voltage-gated potassium channel complex antibodies (p < 0.01). Mean duration from symptom onset to diagnosis, and symptom onset to initiation of immunomodulation was significantly lower among the responders (75 versus 431 days, p < 0.05, and 80 versus 554, p < 0.01, respectively). There was no outcome difference based on gender, MRI characteristics, seizure type, type of acute immunomodulatory therapy, or use of chronic immunomodulation. Among published cases to date, older age, presence of cell-surface antibodies, early diagnosis and immunomodulatory treatment are associated with better seizure outcomes among patients with autoimmune epilepsy.

16 March 2016 in Epilepsy Research and Treatment
Verified
Journal Article
Open access
PDF file
HCHai Chen
Hai Chen
PMPradeep N. Modur
Pradeep N. Modur
NBNiravkumar Barot
Niravkumar Barot
PNPaul C. Van Ness
Paul C. Van Ness
MAMark A. Agostini
Mark A. Agostini
BMBruce Mickey
Bruce Mickey
Objective. We investigated the longitudinal outcome of resective epilepsy surgery to identify the predictors of seizure recurrence. Materials and Methods. We retrospectively analyzed patients who underwent resections for intractable epilepsy over a period of 7 years. Multiple variables were investigated as potential predictors of seizure recurrence. The time to first postoperative seizure was evaluated using survival analysis and univariate analysis at annual intervals. Results. Among 70 patients, 54 (77%) had temporal and 16 (23%) had extratemporal resections. At last follow-up (mean 48 months; range 24–87 months), the outcome was Engel class I in 84% () of patients. Seizure recurrence followed two patterns: recurrence was “early” (within 2 years) in 82% of patients, of whom 83% continued to have seizures despite optimum medical therapy; recurrence was “late” (after 2 years) in 18%, of whom 25% continued to have seizures subsequently. Among the variables of interest, only resection site and ictal EEG remained as independent predictors of seizure recurrence over the long term (). Extratemporal resection and discordance between ictal EEG and resection area were associated with 4.2-fold and 5.6-fold higher risk of seizure recurrence, respectively. Conclusions. Extratemporal epilepsy and uncertainty in ictal EEG localization are independent predictors of unfavorable outcome. Seizure recurrence within two years of surgery indicates poor long-term outcome.